Secondary Hypogonadism in Special Populations

What Makes Secondary Hypogonadism Different From Primary

Secondary hypogonadism originates above the testes. The hypothalamus or pituitary fails to produce adequate gonadotropin-releasing hormone (GnRH), LH, or FSH, so the testes never receive a proper signal to make testosterone or sperm. This distinction matters because the testes themselves remain functional in most cases, which opens the door to therapies that stimulate endogenous production rather than replace it.

The 2018 Endocrine Society Clinical Practice Guideline defines the diagnosis as a total testosterone below 300 ng/dL measured on at least two morning samples, paired with LH that is low or "inappropriately normal" (typically below 8 mIU/mL) 1. That LH criterion is what separates secondary from primary hypogonadism, where LH is typically elevated above 9-10 mIU/mL as the pituitary tries to compensate for failing testes.

The guideline authors state: "Testosterone therapy is recommended for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" 1. However, special populations often require modified approaches. A 35-year-old man with opioid-induced low testosterone who wants children needs an entirely different strategy than a 60-year-old with type 2 diabetes and no fertility goals.

Before starting any treatment, clinicians must rule out reversible causes: medications (opioids, glucocorticoids, anabolic steroids), hyperprolactinemia, iron overload, and pituitary masses. An MRI of the sella turcica is indicated when testosterone falls below 150 ng/dL, when prolactin is elevated, or when visual field defects are present 1.

Obesity and Metabolic Syndrome

Excess adiposity is the single most common reversible driver of secondary hypogonadism in men. Adipose tissue aromatizes testosterone into estradiol, which feeds back on the hypothalamus and suppresses GnRH pulsatility. The result is a functional suppression of the entire axis.

A cross-sectional analysis from the European Male Ageing Study (EMAS, N=3,219) found that BMI was the strongest single predictor of low testosterone, with men in the highest BMI quartile showing a 2.4-fold greater odds of total testosterone below 317 ng/dL compared to normal-weight men 2. Separately, data from NHANES III estimated that up to 57% of men with class II-III obesity (BMI >35) had low free testosterone 3.

Weight loss is the first-line intervention. A meta-analysis of 24 studies (N=3,435) published in the European Journal of Endocrinology reported that lifestyle-induced weight loss of 5-10% increased total testosterone by approximately 2-3 nmol/L (58-86 ng/dL) 4. Bariatric surgery produces even larger gains. The STAMPEDE trial and other surgical cohorts documented testosterone increases of 150-250 ng/dL at 12 months post-procedure 5.

The Endocrine Society recommends against testosterone therapy as first-line for obese men, advising weight loss and metabolic optimization before pharmacologic intervention 1. GLP-1 receptor agonists are changing this picture. The STEP-1 trial (N=1,961) demonstrated 14.9% body weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo 6, and post hoc hormonal analyses from GLP-1 trials consistently show testosterone recovery paralleling weight reduction.

Type 2 Diabetes

The relationship between type 2 diabetes and secondary hypogonadism is bidirectional. Insulin resistance impairs GnRH pulse frequency, while low testosterone worsens insulin sensitivity and visceral fat deposition.

A 2004 cross-sectional study by Dhindsa et al. (N=103) found that 33% of men with type 2 diabetes had low free testosterone with inappropriately low LH, confirming a secondary pattern 7. Larger database analyses place the prevalence of hypogonadism in T2D at 25-40% depending on the assay and threshold used 8.

The American Diabetes Association (ADA) Standards of Care recommend measuring morning total testosterone in men with T2D who report symptoms of hypogonadism (fatigue, low libido, erectile dysfunction) 9. The AACE/ACE 2024 guidelines reinforce this, noting that testosterone screening should be considered in men with T2D and obesity given the high prevalence of the overlap.

The Testosterone Trials (TTrials, N=790) enrolled men aged 65 and older with testosterone below 275 ng/dL and found that one year of transdermal testosterone gel modestly improved sexual function, walking distance, and mood, but did not improve vitality or cognitive function 10. Glycemic outcomes were not a primary endpoint, though the TIMES2 trial (N=220) showed that testosterone replacement in hypogonadal men with T2D improved insulin resistance (HOMA-IR) by 15.2% over 6 months 11.

Weight loss remains the backbone. Testosterone therapy may be considered an adjunct when symptoms persist after metabolic optimization, particularly in men who are not seeking fertility.

Opioid-Induced Hypogonadism

Chronic opioid therapy suppresses the HPG axis at the hypothalamic level. Opioids directly inhibit GnRH neurons in the arcuate nucleus, and the suppression can begin within days of starting therapy.

Vuong et al. published a systematic review (2010) reporting that approximately 75% of men receiving long-term opioid therapy (defined as daily use for three months or longer) had testosterone levels below the normal range 12. The Endocrine Society guideline specifically lists opioids as a common reversible cause and recommends discontinuation or dose reduction as the first step 1.

When opioid tapering is not feasible, as is common in palliative care or medication-assisted treatment for opioid use disorder, testosterone replacement is appropriate. One key consideration: men on methadone or buprenorphine maintenance who desire fertility should receive hCG (1,500-3 to 000 IU two to three times weekly) or enclomiphene (25 mg daily) rather than exogenous testosterone, because testosterone shuts down remaining gonadotropin secretion and suppresses spermatogenesis 13.

The Endocrine Society guideline authors write: "In men who desire fertility, we recommend against using testosterone therapy and instead suggest treatment with gonadotropins or selective estrogen receptor modulators" 1. This recommendation applies across all special populations but is particularly relevant in opioid-induced cases because the affected demographic skews younger (ages 25-45) and includes many men who have not yet completed their families.

HIV-Associated Hypogonadism

Hypogonadism occurs in 20-50% of HIV-positive men, though prevalence has declined since the widespread adoption of effective antiretroviral therapy (ART). The etiology is often mixed: viral proteins, chronic inflammation, and certain antiretrovirals (particularly older protease inhibitors) suppress the axis at both hypothalamic and gonadal levels 14.

Body composition changes are a major driver of screening in this group. HIV-associated lipodystrophy and wasting overlap clinically with hypogonadal symptoms. A meta-analysis by Bhasin et al. demonstrated that testosterone replacement in HIV-positive men with documented low testosterone significantly increased lean body mass by 1.2-2.5 kg over 12-24 weeks compared to placebo 15.

The Infectious Diseases Society of America (IDSA) HIV primary care guidelines recommend checking testosterone in HIV-positive men with fatigue, unexplained weight loss, decreased libido, or reduced bone mineral density 16. The Endocrine Society guideline similarly recommends testosterone measurement in HIV-positive men with symptoms 1.

Monitoring in this population requires attention to drug interactions. Testosterone is metabolized via CYP3A4, and certain ART regimens (ritonavir-boosted protease inhibitors) can alter testosterone clearance. SHBG levels are frequently disrupted. Free testosterone by equilibrium dialysis or calculated free testosterone is preferred over total testosterone alone when SHBG abnormalities are suspected 1.

Chronic Kidney Disease and Dialysis

Uremia disrupts the HPG axis at multiple levels. In early CKD (stages 3-4), the pattern is predominantly secondary, with blunted GnRH pulsatility from uremic toxins and elevated prolactin. As CKD progresses to dialysis, primary gonadal damage from oxidative stress often coexists, creating a mixed picture.

Approximately 50% of men on hemodialysis have testosterone levels below 300 ng/dL 17. A prospective cohort study of 2,489 men initiating dialysis found that low testosterone was independently associated with increased all-cause mortality (hazard ratio 1.29 to 95% CI 1.06-1.57) 18.

Despite the high prevalence and prognostic implications, no large randomized trial has evaluated testosterone therapy specifically in men on dialysis. The Endocrine Society guideline acknowledges this gap and does not make a strong recommendation for or against treatment in CKD/ESRD. Small pilot studies (N=30-60) suggest that intramuscular testosterone cypionate 200 mg every two weeks improved lean mass and functional capacity in dialysis patients, but these findings need replication 19.

Erythropoiesis-stimulating agent (ESA) requirements may decrease with testosterone therapy, given testosterone's known stimulatory effect on erythropoietin and red blood cell production. Polycythemia monitoring is mandatory: hematocrit checks at baseline, 3 months, 6 months, and then annually, with a threshold of 54% for dose reduction or therapy cessation 1.

Hemochromatosis and Iron Overload

Iron deposition in the pituitary gonadotroph cells is a classic but underrecognized cause of secondary hypogonadism. Hereditary hemochromatosis (HFE gene mutations, most commonly C282Y homozygosity) affects approximately 1 in 200 people of Northern European descent, and hypogonadism is one of its earliest endocrine manifestations.

A study of 32 men with hereditary hemochromatosis found that 62.5% had biochemical hypogonadism, with the majority showing a secondary pattern 20. Transferrin saturation above 45% and ferritin above 300 ng/mL should prompt HFE genotyping 21.

Phlebotomy is the primary treatment. Testosterone may recover after iron depletion if pituitary damage is not yet irreversible, though recovery can take 6-12 months of regular phlebotomy. When testosterone does not normalize despite adequate iron reduction, testosterone replacement or gonadotropin therapy is indicated depending on fertility goals. MRI of the pituitary with iron-sensitive sequences (T2-weighted) can help assess the degree of iron deposition 20.

Glucocorticoid-Induced Hypogonadism

Chronic exogenous glucocorticoid use suppresses GnRH at the hypothalamic level and directly inhibits gonadotropin release from the pituitary. Doses as low as prednisone 7.5 mg daily for more than three months can measurably suppress the HPG axis.

A cohort analysis of men receiving chronic glucocorticoids for rheumatologic conditions found that 50% had total testosterone below 300 ng/dL 22. The AACE guidelines recommend testosterone screening in men on chronic glucocorticoids who report fatigue, sexual dysfunction, or who have low bone mineral density on DEXA scanning.

Dose reduction or discontinuation reverses the suppression in most cases. When ongoing glucocorticoid therapy is medically necessary, testosterone replacement should be considered both for symptom relief and for bone protection. The combination of a glucocorticoid and untreated hypogonadism places patients at compounded fracture risk.

Fertility-Preserving Approaches Across Populations

Exogenous testosterone, whether delivered as injections, gels, or pellets, suppresses intratesticular testosterone production and spermatogenesis. For men who want to conceive now or in the future, the preferred agents stimulate the endogenous axis.

Enclomiphene (a selective estrogen receptor modulator) blocks estrogen feedback at the hypothalamus, increasing GnRH, LH, and FSH secretion. In a randomized trial (N=125) of men with secondary hypogonadism, enclomiphene 25 mg daily raised total testosterone from a mean of 228 ng/dL to 441 ng/dL at 16 weeks while maintaining or improving sperm parameters 23.

Human chorionic gonadotropin (hCG) directly stimulates Leydig cells via the LH receptor. Standard dosing for hypogonadotropic hypogonadism is 1,500-3 to 000 IU subcutaneously two to three times per week. When fertility induction is the goal, hCG is often combined with recombinant FSH (75-150 IU three times weekly) for men with very low gonadotropin levels, such as those with congenital hypogonadotropic hypogonadism or pituitary tumors 24.

GnRH pulsatile therapy delivered via a subcutaneous pump is the most physiologic approach for hypothalamic causes (Kallmann syndrome, functional hypothalamic suppression) but is limited by cost, device availability, and logistical burden. It remains more commonly used in Europe and specialized centers 25.

The choice among these agents depends on the underlying cause, fertility timeline, and patient preference. Across all special populations discussed, the principle is consistent: if fertility is desired, avoid exogenous testosterone and use agents that preserve or restore endogenous gonadotropin secretion.

Monitoring and Safety Across All Populations

Regardless of the population or treatment chosen, the 2018 Endocrine Society guideline recommends the following monitoring schedule for men on testosterone therapy: measure testosterone at 3 months (trough level for injectables, any-time level for gels), hematocrit at baseline and at 3, 6, and 12 months, PSA at 3-12 months in men over 40, and a digital rectal exam at the clinician's discretion 1.

Polycythemia (hematocrit above 54%) is the most common adverse effect requiring intervention. It occurs more frequently in men on injectable testosterone than transdermal formulations, and men with CKD on ESAs or those living at high altitude are at amplified risk. Reduce the dose, switch to a transdermal route, or perform therapeutic phlebotomy.

Cardiovascular safety remains under study. The TRAVERSE trial (N=5,246), the first adequately powered cardiovascular outcomes trial of testosterone, found that transdermal testosterone in men aged 45-80 with hypogonadism and cardiovascular risk factors did not increase the rate of major adverse cardiovascular events (MACE) over a median follow-up of 33 months (hazard ratio 0.96 to 95% CI 0.78-1.17) 26. This trial provided reassurance but was not powered to evaluate subgroups like CKD or HIV.

Bone mineral density should be assessed by DEXA at baseline and every 1-2 years in men started on testosterone for hypogonadism, particularly those with additional risk factors for osteoporosis (glucocorticoid use, CKD, HIV).

Men on testosterone therapy should have a PSA below 4.0 ng/mL and no palpable prostate abnormalities before initiation. A PSA rise exceeding 1.4 ng/mL within 12 months of starting therapy warrants urologic evaluation 1.